The FDA has granted a Fast Track designation to the combination of balstilimab, a PD-1 inhibitor, and zalifrelimab, a CTLA-inhibitor, for the treatment of patients with relapsed or refractory metastatic cervical cancer reports Agenus. Fast Track Designation is...